Gw Pharma: Fda and Cannabidiol Cbd

gw pharma: The FDA has asked for a response from the company within 15 working days, saying how it plans to address the violations, according to Market Watch. Failure to correct the violations promptly may result in legal action, including product seizure and injunction, said the letter. Curaleaf CURLF, 0.00% is illegally selling unapproved products containing cannabidiol CBD online with unsubstantiated claims that the products treat cancer, Alzheimer's disease, opioid withdrawal, pain and pet anxiety, among other conditions or diseases, the FDA wrote. The move is the first against a multi-state operator and is expected to shake the entire sector. But the FDA views CBD as a drug, because it's the main ingredient in the only cannabis-based drug it has approved GW Pharma's Epidiolex, a treatment for severe childhood epilepsy. CBD, a non-intoxicating ingredient in cannabis, is widely held to have wellness benefits and many companies are waiting for the FDA to create rules before launching product lines. (news.financializer.com). As reported in the news.